Effects of VERApamil versus metoprolol to prevent progression from Paroxysmal to persistent Atrial Fibrillatio
Phase 4
Withdrawn
- Conditions
- atrial fibrillationatrial rhythm disorder10007521
- Registration Number
- NL-OMON44431
- Lead Sponsor
- Martini Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
In order to be eligible to participate in this trial, a subject must meet all of the following criteria:
Patients (age >= 18) with symptomatic paroxysmal AF with an indication for rate control medication who participate in the RACE 5 registry. Patients must be able and willing to sign informed consent for the randomised study.
Exclusion Criteria
Exclusion criteria are (history of) persistent AF, previous adverse effects to the study drugs, heart failure with reduced ejection fraction, symptomatic hypotension, atrioventricular conduction disturbance, severe asthma/COPD, history of pulmonary vein isolation (PVI), pregnancy and breastfeeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method